The NHS is launching an innovative pilot scheme to provide the weight loss injection Mounjaro (tirzepatide) to adults battling obesity. The drug, already approved for type 2 diabetes in the UK, has shown remarkable results in clinical trials, with participants losing up to 20% of their body weight.
How Does Mounjaro Work?
Mounjaro works by mimicking two key hormones—GLP-1 and GIP—which regulate appetite and insulin sensitivity. This dual-action approach helps users feel fuller for longer while improving metabolic health.
Who Will Qualify?
The pilot will initially target adults with a BMI over 30 (or 27 with weight-related health conditions). Eligible participants will receive weekly injections alongside dietary and lifestyle support.
Why This Matters
Obesity affects one in four UK adults and costs the NHS billions annually. If successful, this programme could revolutionise weight management, reducing pressure on healthcare services and improving long-term patient outcomes.
Safety and Availability
While generally well-tolerated, common side effects include nausea and digestive discomfort. The NHS emphasises that Mounjaro should complement—not replace—healthy habits. Wider rollout depends on pilot results and NICE approval.
